• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects
Commentary on: Porsteinsson AP, Drye LT, Pollock BG, et al.. Effect of citalopram on agitation in Alzheimer disease. The CitAD randomised clinical trial. JAMA 2014;311:682–91. Context By 2050, an estimated 135 million people will suffer from dementia globally.1 Caring for those with Alzheimer's disease (AD)—by far the most common form of dementia—is expensive, costing an estimated £23 billion per annum in the UK. As the disease progresses, neuropsychiatric symptoms such as depression, agitation and behavioural disturbance appear. The incidence of these symptoms, which predict institutionalisation an...
Source: Evidence-Based Medicine - September 15, 2014 Category: Internal Medicine Authors: Underwood, B. R., Fox, C. Tags: Neurogastroenterology, Geriatric medicine, Dementia, Drugs: CNS (not psychiatric), Sleep disorders (neurology), Stroke, Drugs: psychiatry, Eating disorders, Memory disorders (psychiatry), Psychiatry of old age, Psychotic disorders (incl schizophrenia), Sl Source Type: research

Effectiveness and safety of Wuling capsule for post stroke depression: A systematic review.
CONCLUSION: Wuling capsule appeared to present certain antidepressant effect compared to no treatment control. With a combination of several Western medicines, Wuling capsule could be helpful in strengthening efficacy and reducing the incidence of adverse events as an alternative choice in the treatment of PSD. However, due to the limited number of included trials and relatively moderate methodological quality in the majority of studies, further large scale and rigorously designed trials are warranted to confirm the effectiveness and safety of Wuling capsule for post stroke depression. PMID: 24906594 [PubMed - as supplied by publisher]
Source: Complementary Therapies in Medicine - June 1, 2014 Category: Complementary Medicine Authors: Peng L, Zhang X, Kang DY, Liu XT, Hong Q Tags: Complement Ther Med Source Type: research

A Case Report of Acute Intracerebral Vascular Ischemic Stroke After Treatment with Dihydroergotamine in a * Patient with New Onset of Migraine New Daily Persistant Headache with Thunderclap Onset (S41.008)
CONCLUSIONS: We report this case of a Stroke occuring in a patient who failed conventional outpatient management of sudden onset migraine-like headache that we suspect may have been on the spectrum of RCVS. Prior to this no reports have been published on a stroke possibly being a side effect or complication of DHE therapy. One prior report has suggested DHE caused RCVS in a migraine patient on citalopram, supporting the concept that DHE should be avoided in the setting of recent onset RCVS.Disclosure: Dr. Ghafoor has nothing to disclose. Dr. Young has received personal compensation for activities with Merck & Co. Inc. ...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Ghafoor, S., Young, W. Tags: Headache: Clinical Source Type: research

Is this Dementia or Alcohol Intoxication or Both?
I am presenting the case of an independent lady whose active alcohol abuse masked her new onset dementia. Ms. G is a 76 year old female who lives alone in a continuum of care retirement community. She has difficult-to-control hypertension, hypothyroidism, B12 deficiency, anxiety, and adjustment disorder which started after her husband, who was an alcoholic, committed suicide. She struggled with alcohol abuse herself through the years. She takes citalopram, amlodipine, B12 injections, and vitamin D supplements. She has lived in this community for 4 years. She has made new friends and currently has a new boyfriend, with who...
Source: Journal of the American Medical Directors Association - February 25, 2013 Category: Health Management Authors: Wanda Colón Cartagena, Wanda Colón Cartagena, Sandra Bellantonio Tags: Poster Abstracts Source Type: research

A Case Report of Dihydroergotamine Administration for Status Migrainosus in a Patient on Longstanding Citalopram Causing a Fatal Reversible Cerebral Vasoconstriction Syndrome (RCVS) (P02.027)
CONCLUSIONS: We report this case report of fatal RCVS of a patient on long standing citalopram who developed this after being administered Dihydroergotamine for status migrainosus. As this is thought to be a self-limiting in terms of clinical features. However, some patients may have more severe focal neurologic symptoms and signs, including ischemic or hemorrhagic strokes as described in our patient.Disclosure: Dr. Asi has nothing to disclose. Dr. Gomes has nothing to disclose. Dr. Dani has nothing to disclose.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Asi, K., Gomes, J., Dani, D. Tags: P02 Cerebrovascular Disease II Source Type: research

Pages: 1  2  3